A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Primary Purpose
Solid Tumor
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
KD033 (SAR445710)
Sponsored by

About this trial
This is an interventional treatment trial for Solid Tumor
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.
- Measurable disease per RECIST v1.1 guidelines.
- Life expectancy of at least 3 months.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.
- Adequate organ and bone marrow functions.
- All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non significant or stable on supportive care.
- All subjects, male and female, who are not surgically sterilized or postmenopausal must agree to use "highly effective methods of contraception" during the study and for at least 60 days after the last dose of KD033.
- Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 treatment.
- Ability to understand the purpose of the study, provide signed and dated informed consent from the subject/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.
- Subjects must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.
Exclusion Criteria:
- Use of immunotherapy, biological therapy, cytokine therapy < 21 days prior to the first dose of study drug.
- Use of immunomodulating agents < 21 days prior to the first dose of study drug.
- Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy < 14 days prior to the first dose of study drug.
- Anti PD-L1 or anti PD-1 therapy < 6 weeks prior to the first dose of study drug.
- Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.
- Use of any investigational drug or have major surgery within 28 days before the start of trial treatment
- Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.
- Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment.
- Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.
- History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Subjects with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.
- Receipt of any organ transplantation including hematopoietic cell transplantation.
- Has a paraneoplastic syndrome of autoimmune nature.
- History of interstitial lung disease or severe obstructive pulmonary disease.
- Clinically significant cardiovascular/cerebrovascular disease.
- QTc(F) interval > 450 ms for men or > 470 ms for women)
- Left ventricular ejection fraction (LVEF) < 50% as measured by an echocardiogram (ECHO).
- Active infection requiring therapy.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.
- Pregnant or breast-feeding women
- Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis
- Vaccine administration within 4 weeks of investigational drug administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 administration and during the treatment phase,; however, it is preferred to not vaccinate during the 28-day DLT period.
Other protocol-defined exclusion criteria could apply.
Sites / Locations
- UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042Recruiting
- Moffitt Cancer Center - Site 102Recruiting
- Roswell Park Cancer Institute - 665 Elm St - Site 062Recruiting
- Fox Chase Cancer Center - 333 Cottman Avenue - Site 141Recruiting
- University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Bi-weekly Monotherapy Dose Escalation (Q2W)
Weekly Monotherapy Dose Escalation (Q1W)
Dose Expansion
Arm Description
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
Outcomes
Primary Outcome Measures
Occurrence of Dose Limiting Toxicities (DLTs)
To evaluate the number of participants who experienced DLTs during the dose escalation phase
Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity
To evaluate the number of TEAEs and treatment-related AEs by severity for all dose groups/cohorts according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Secondary Outcome Measures
Best Overall Response (BOR)
To evaluate the best overall response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment
Duration Of Response (DOR)
To evaluate the duration of response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment
Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - AUC
Area under the concentration versus time curve (AUC)
Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - Cmax
Maximum plasma concentration observed (Cmax)
Exploration of Anti-KD033 (SAR445710) Antibodies
To evaluate serum titers and assessment of neutralization of anti-KD033 (SAR445710) antibodies using blood samples collected during the dose escalation and dose expansion phases
Full Information
NCT ID
NCT04242147
First Posted
January 23, 2020
Last Updated
September 8, 2023
Sponsor
Kadmon, a Sanofi Company
1. Study Identification
Unique Protocol Identification Number
NCT04242147
Brief Title
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Official Title
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 3, 2020 (Actual)
Primary Completion Date
September 25, 2025 (Anticipated)
Study Completion Date
July 3, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kadmon, a Sanofi Company
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a Phase1, open-label, sequential dose-escalation and dose-expansion study of KD033 (SAR445710) in adult participants with advanced or metastatic solid tumors. The main purpose of this study is to test KD033 (SAR445710) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks and when given weekly. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
Detailed Description
The foreseen treatment duration is until disease progression, unacceptable toxicity, criterion for withdrawal or for a maximum of 2 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Bi-weekly Monotherapy Dose Escalation (Q2W)
Arm Type
Experimental
Arm Description
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
Arm Title
Weekly Monotherapy Dose Escalation (Q1W)
Arm Type
Experimental
Arm Description
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
Arm Title
Dose Expansion
Arm Type
Experimental
Arm Description
KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
Intervention Type
Drug
Intervention Name(s)
KD033 (SAR445710)
Intervention Description
Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
Primary Outcome Measure Information:
Title
Occurrence of Dose Limiting Toxicities (DLTs)
Description
To evaluate the number of participants who experienced DLTs during the dose escalation phase
Time Frame
Up to 28 days
Title
Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity
Description
To evaluate the number of TEAEs and treatment-related AEs by severity for all dose groups/cohorts according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Time Frame
Up to 30 days after last treatment
Secondary Outcome Measure Information:
Title
Best Overall Response (BOR)
Description
To evaluate the best overall response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment
Time Frame
Through study completion, an expected average of 1 year
Title
Duration Of Response (DOR)
Description
To evaluate the duration of response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment
Time Frame
Through study completion, an expected average of 1 year
Title
Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - AUC
Description
Area under the concentration versus time curve (AUC)
Time Frame
Through study completion, an expected average of 1 year
Title
Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - Cmax
Description
Maximum plasma concentration observed (Cmax)
Time Frame
Through study completion, an expected average of 1 year
Title
Exploration of Anti-KD033 (SAR445710) Antibodies
Description
To evaluate serum titers and assessment of neutralization of anti-KD033 (SAR445710) antibodies using blood samples collected during the dose escalation and dose expansion phases
Time Frame
Through study completion, an expected average of 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.
Participants must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.
Measurable disease at baseline per RECIST v1.1 guidelines.
Life expectancy of at least 3 months.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.
Adequate organ and bone marrow functions.
All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non-significant or stable on supportive care.
All participants, male and female, who are not surgically sterilized or postmenopausal must agree to use 'highly effective methods of contraception' during the study and for at least 60 days after the last dose of KD033 (SAR445710).
Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 (SAR445710) treatment.
Ability to understand the purpose of the study, provide signed and dated informed consent from the participant/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.
Exclusion Criteria:
Use of immunotherapy, biological therapy, cytokine therapy < 21 days prior to the first dose of study drug.
Use of immunomodulating agents < 21 days prior to the first dose of study drug.
Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy < 14 days prior to the first dose of study drug.
Anti PD-L1 or anti PD-1 therapy < 6 weeks prior to the first dose of study drug.
Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.
Use of any investigational drug or have major surgery within 28 days before the start of trial treatment
Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.
Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment with the exception of corticosteroid replacement therapy for adrenal insufficiency
Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.
History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Participants with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.
Receipt of any organ transplantation including hematopoietic cell transplantation.
Has a paraneoplastic syndrome of autoimmune nature.
History of interstitial lung disease or severe obstructive pulmonary disease.
Clinically significant cardiovascular/cerebrovascular disease.
QTc(F) interval > 450 ms for men or > 470 ms for women)
Left ventricular ejection fraction (LVEF) < 50% as measured by an echocardiogram (ECHO).
Active infection requiring therapy.
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.
Pregnant or breast-feeding women
Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis
Vaccine administration within 4 weeks of investigational drug administration.
Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 (SAR445710) administration and during the treatment phase, however, it is preferred to not vaccinate during the 28-day DLT period.
Note: Other protocol-defined exclusion criteria could apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Trial Transparency email recommended (Toll free number for US & Canada)
Phone
800-633-1610
Ext
option 6
Email
Contact-US@sanofi.com
Facility Information:
Facility Name
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Lim
Phone
310-633-8400
Ext
16043
Email
christopherlim@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
MD
First Name & Middle Initial & Last Name & Degree
Lee S Rosen, MD
Facility Name
Moffitt Cancer Center - Site 102
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adel Yazdankhahkenary
Phone
813-745-6100
Email
Adel.Yazdankhahkenary@moffitt.org
First Name & Middle Initial & Last Name & Degree
Ahmad Tarhini, MD
Facility Name
Roswell Park Cancer Institute - 665 Elm St - Site 062
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Horn
Phone
716-845-1300
Ext
4924
Email
emilycaroline.horn@roswellpark.org
First Name & Middle Initial & Last Name & Degree
Christos Fountzilas, MD
Facility Name
Fox Chase Cancer Center - 333 Cottman Avenue - Site 141
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dana Haagen, BA, BS
Phone
215-214-3908
Email
Dana.Haagen@fccc.edu
First Name & Middle Initial & Last Name & Degree
Anthony Olszanski, MD
Facility Name
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Behr
Phone
412-623-6028
Email
IDDCReferrals@upmc.edu
First Name & Middle Initial & Last Name & Degree
Jason Luke, MD, FACP
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Learn more about this trial
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
We'll reach out to this number within 24 hrs